These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 12666586)

  • 41. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
    Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
    Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
    Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New vaccination strategies for low- and non-responders to hepatitis B vaccine.
    Rendi-Wagner P; Wiedermann G; Stemberger H; Kollaritsch H
    Wien Klin Wochenschr; 2002 Mar; 114(5-6):175-80. PubMed ID: 12238305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Declining prevalence of hepatitis B virus infection in Catalonia (Spain) 12 years after the introduction of universal vaccination.
    Salleras L; Domínguez A; Bruguera M; Plans P; Costa J; Cardeñosa N; Batalla J; Plasència A
    Vaccine; 2007 Dec; 25(52):8726-31. PubMed ID: 18045753
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination.
    Sjogren MH
    Am J Med; 2005 Oct; 118 Suppl 10A():34S-39S. PubMed ID: 16271539
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Repeated-measures models to evaluate a hepatitis B vaccination programme.
    Renard D; Bruckers L; Molenberghs G; Vellinga A; Van Damme P
    Stat Med; 2001 Mar; 20(6):951-63. PubMed ID: 11252015
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies.
    Gandhi RT; Wurcel A; Lee H; McGovern B; Shopis J; Geary M; Sivamurthy R; Sax PE; Ukomadu C
    J Infect Dis; 2005 May; 191(9):1435-41. PubMed ID: 15809901
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune responses to recombinant Mycobacterium smegmatis expressing fused core protein and preS1 peptide of hepatitis B virus in mice.
    Yue Q; Hu X; Yin W; Xu X; Wei S; Lei Y; Lü X; Yang J; Su M; Xu Z; Hao X
    J Virol Methods; 2007 Apr; 141(1):41-8. PubMed ID: 17197041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Efficacy and immune memory of plasma-derived hepatitis B vaccine 11 years after primary immunization].
    Xu H; Zhuang G; Wang X; Chen Q; Chen Z
    Zhonghua Yu Fang Yi Xue Za Zhi; 2000 Mar; 34(2):113-5. PubMed ID: 11860915
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Performance of the DiaSorin LIAISON(®) anti-HBs II for the detection of hepatitis B surface antibodies: comparison with the Abbott Architect anti-HBs assay.
    Kinn S; Akhavan S; Agut H; Thibault V
    J Clin Virol; 2011 Apr; 50(4):297-302. PubMed ID: 21330194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Seroepidemiology of hepatitis B in Greek children 6 years after the implementation of universal vaccination.
    Papaevangelou V; Hadjichristodoulou C; Cassimos DC; Pantelaki K; Tzivaras A; Hatzimichael A; Theodoridou M
    Infection; 2008 Mar; 36(2):135-9. PubMed ID: 18231718
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C.
    Kallinowski B; Jilg W; Buchholz L; Stremmel W; Engler S
    Z Gastroenterol; 2003 Oct; 41(10):983-90. PubMed ID: 14562195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The assessment of efficacy of hepatitis B prophylaxis in children with acute lymphoblastic leukemia].
    Moryl-Bujakowska A; Czogała M; Czogała W; Balwierz W
    Przegl Lek; 2004; 61 Suppl 2():85-8. PubMed ID: 15686054
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Seroprotection after hepatitis B vaccination in children aged 1 to 15 years in central province of Iran, Semnan.
    Rezaei M; Nooripoor S; Ghorbani R; Ramezanshams F; Mamishi S; Mahmoudi S
    J Prev Med Hyg; 2014 Mar; 55(1):1-3. PubMed ID: 25916024
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Humoral immunological response in laboratory animals after vaccination with recombinant vaccines against viral hepatitis B of different generations].
    Górska P
    Przegl Epidemiol; 2007; 61(2):393-400. PubMed ID: 17956059
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Comparison of immunogenicity and safety of Engerix B and Twinrix vaccine].
    Gałaj A; Grześk G; Borys D; Durmowicz A; Grześk E; Szadujkis-Szadurski L
    Wiad Lek; 2004; 57(5-6):217-20. PubMed ID: 15518064
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HBV and HCV infection in Japanese dental care workers.
    Nagao Y; Matsuoka H; Kawaguchi T; Ide T; Sata M
    Int J Mol Med; 2008 Jun; 21(6):791-9. PubMed ID: 18506374
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions.
    van den Berg R; van Hoogstraten I; van Agtmael M
    AIDS Rev; 2009; 11(3):157-64. PubMed ID: 19654857
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines.
    Zuckerman JN
    J Med Virol; 2006 Feb; 78(2):169-77. PubMed ID: 16372285
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine.
    Shafran SD; Mashinter LD; Lindemulder A; Taylor GD; Chiu I
    HIV Med; 2007 Jul; 8(5):295-9. PubMed ID: 17561875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.